Table 1.
Correlation between bone mineral density magnitude and factors of all subjects in each part with P-value.
| Factor | Population or mean value | LS | FN | TH | GT |
|---|---|---|---|---|---|
| Being RA patient | 323 (43.6) | 0.126 | 0.001 | 0.001 | 0.003 |
| Age | 79.2 ± 10.2 | 0.216 | 0.792 | 0.330 | 0.021 |
| Being male | 72 (9.7) | 0.136 | 0.356 | 0.151 | 0.001 |
| Current GCS administration | 42 (5.7) | 0.099 | 0.315 | 0.629 | 0.357 |
| Current GCS dose, mg/day | 3.5 ± 2.6 | 0.084 | 0.078 | 0.037 | 0.003 |
| GCS administrated | 228 (30.8) | 0.366 | 0.732 | 0.752 | 0.305 |
| Mean cumulative GCS dose, mg | 203.8 ± 604.7 | 0.129 | 0.603 | 0.853 | 0.554 |
| Osteoporosis drug intervention | 522 (70.4) | 0.527 | 0.001 | 0.001 | 0.001 |
| Past bone fragility fracture | 223 (30.1) | 0.914 | 0.276 | 0.443 | 0.934 |
| Frailty score | 2.4 ± 2.3 | 0.224 | 0.212 | 0.311 | 0.152 |
| Barthel Index | 70.1 ± 25.8 | 0.985 | 0.401 | 0.015 | 0.156 |
| Body mass index | 21.9 ± 10.2 | 0.005 | 0.231 | 0.049 | 0.006 |
| Cr/CysC | 0.661 ± 0.134 | 0.316 | 0.104 | 0.852 | 0.554 |
| Dementia treated | 205 (27.5) | 0.723 | 0.545 | 0.642 | 0.504 |
| No. of comorbidities | 11.4 ± 6.2 | 0.001 | 0.553 | 0.929 | 0.925 |
Values are presented as number (%) or mean ± standard deviation.
LS, lumbar spine; FN, femoral neck; TH, total hip; GT, greater trochanter; RA, rheumatoid arthritis; GCS, glucocorticoid steroid; Cr/CysC, serum creatinine to cystatin C ratio.
In LS, FN, TH, and GT columns, P-value with multiple linear regression analysis are shown.
Plain style shows positive correlation and italic style shows negative correlation.
Bold style with large points shows significant positive correlation (P < 0.05), and bold style with large points and with underline shows significant negative correlation (P < 0.05). Small pointed number shows no significant correlation (P > 0.05).